ClinVar Miner

Submissions for variant NM_002878.3(RAD51D):c.394G>A (p.Val132Ile) (rs201141245)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 11
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Ambry Genetics RCV000164547 SCV000215203 likely benign Hereditary cancer-predisposing syndrome 2018-08-06 criteria provided, single submitter clinical testing Other strong data supporting benign classification
GeneDx RCV000588322 SCV000292678 uncertain significance not provided 2020-10-30 criteria provided, single submitter clinical testing In silico analysis supports that this missense variant does not alter protein structure/function; Observed in individuals with personal and/or family history of breast or ovarian cancer (Thompson 2013, Song 2015, Kraus 2017, Tsai 2018); This variant is associated with the following publications: (PMID: 23372765, 26261251, 27616075, 30374176, 29300386, 31159747, 32426482)
Invitae RCV000458927 SCV000551340 uncertain significance Breast-ovarian cancer, familial 4 2020-10-21 criteria provided, single submitter clinical testing This sequence change replaces valine with isoleucine at codon 132 of the RAD51D protein (p.Val132Ile). The valine residue is highly conserved and there is a small physicochemical difference between valine and isoleucine. This variant is present in population databases (rs201141245, ExAC 0.03%), and has an allele count higher than expected for a pathogenic variant (PMID: 28166811). This variant has been reported observed in individuals affected with breast and/or ovarian cancer (PMID: 27616075, 23372765, 26261251). ClinVar contains an entry for this variant (Variation ID: 185178). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated, but these predictions have not been confirmed by published functional studies and their clinical significance is uncertain. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000588322 SCV000698100 uncertain significance not provided 2017-04-20 criteria provided, single submitter clinical testing Variant summary: The c.394G>A (p.Val132Ile) in RAD51D gene is a missense change that involves a non-conserved nucleotide. Although the variant is located within the ATP binding site of conserved domain Rad51_DMC1_radA, 4/5 in silico tools predict benign outcome. The variant is present in the large control population dataset of ExAC and gnomAD at a similar frequencies of 0.00007 (9/121398 and 17/277162 chrs tested, respectively), predominantly in individuals of African descent (0.0002884; 3/10404 and 6/24020 chrs tested) which exceeds the maximal expected frequency of a pathogenic allele (0.00012) in this gene. The variant has been reported in at least 1 sporadic brC case (Kraus, 2017) and 2 BrC families without strong evidence for causality (Thompson, 2013; Song, 2015). Lastly, several reputable databases/clinical laboratories cite the variant with classification of VUS but favoring the benign nature of this change. Taking all line of evidence into consideration, the variant was conservatively classified as VUS-Possibly Benign.
Counsyl RCV000458927 SCV000784995 uncertain significance Breast-ovarian cancer, familial 4 2017-03-06 criteria provided, single submitter clinical testing
GeneKor MSA RCV000164547 SCV000822177 uncertain significance Hereditary cancer-predisposing syndrome 2018-08-01 criteria provided, single submitter clinical testing
University of Washington Department of Laboratory Medicine, University of Washington RCV000458927 SCV000886447 likely benign Breast-ovarian cancer, familial 4 2018-05-09 criteria provided, single submitter research The RAD51D variant designated as NM_002878.3:c.394G>A (p.Val132Ile) is classified as likely benign. This variant is listed in ClinVar (Variation ID: 141739) and has been classified as likely benign by another laboratory. Computer software programs (SIFT, Polyphen-2, Align-GVGD) all predict that this variant is likely to be tolerated. In one observed family, this variant was not detected in an affected relativer’s ovarian tumor, which indicates that it is unlikely to be the cause of her ovarian cancer. Bayesian analysis integrating all of this data (Tavtigian et al, 2018, PMID:29300386) gives about a 3% probability of pathogenicity, which is consistent with a classification of likely benign. This variant is not predicted to alter RAD51D function or modify cancer risk. A modest (less than 2 fold) increase in cancer risk due to this variant cannot be entirely excluded. This analysis was performed in conjunction with the family studies project as part of the University of Washington Find My Variant Study.
Color Health, Inc RCV000164547 SCV000910748 likely benign Hereditary cancer-predisposing syndrome 2016-02-22 criteria provided, single submitter clinical testing
CeGaT Praxis fuer Humangenetik Tuebingen RCV000588322 SCV001151270 uncertain significance not provided 2017-04-01 criteria provided, single submitter clinical testing
Quest Diagnostics Nichols Institute San Juan Capistrano RCV000588322 SCV001470090 uncertain significance not provided 2020-01-02 criteria provided, single submitter clinical testing
Department of Pathology and Laboratory Medicine,Sinai Health System RCV001356158 SCV001551245 uncertain significance Malignant tumor of breast no assertion criteria provided clinical testing The RAD51D p.Val132Ile variant was identified in 4 of 10,140 proband chromosomes (frequency: 0.0004) from individuals with breast and ovarian cancer and was not identified in 6476 control chromosomes from healthy individuals (Kraus 2017, Thompson 2013, Song 2015). The variant was identified in dbSNP (rs201141245) as “with uncertain significance allele”, in ClinVar (interpreted as "uncertain significance" by Invitae and 4 others, "likely benign" by Ambry Genetics and 3 others). The variant was identified in control databases in 17 of 277,162 chromosomes at a frequency of 0.00006 (Genome Aggregation Database Feb 27, 2017). The variant was observed in the following populations: African in 6 of 24,020 chromosomes (freq: 0.0003), Latino in 4 of 34,418 chromosomes (freq: 0.0001), European in 6 of 126,668 chromosomes (freq: 0.00005), Finnish in 1 of 25,788 chromosomes (freq: 0.00004); it was not observed in the “Other”, Ashkenazi Jewish, East Asian and South Asian populations. The variant was observed in our laboratory in an individual with a likely pathogenic BRCA1 variant (p.Val1833Met). The p.Val132 residue is conserved in in mammals but not in more distantly related organisms however computational analyses (PolyPhen-2, SIFT, AlignGVGD, BLOSUM, MutationTaster) do not suggest a high likelihood of impact to the protein; this information is not predictive enough to rule out pathogenicity. The variant occurs outside of the splicing consensus sequence and in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer) do not predict a difference in splicing. In summary, based on the above information the clinical significance of this variant cannot be determined with certainty at this time. This variant is classified as a variant of uncertain significance.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.